Former FDA Deputy Commissioner Deb Autor Named CEO of Healthcare Innovation Catalysts

Former FDA Deputy Commissioner Deb Autor Named CEO of Healthcare Innovation Catalysts

February 2, 2024 : A landmark transition within the life sciences advisory landscape transpired today with the announcement of Deborah M. Autor, the former Deputy Commissioner of the U.S. Food and Drug Administration (FDA), as the inaugural Chief Executive Officer of Healthcare Innovation Catalysts (HIC). This strategic appointment positions HIC to leverage Ms. Autor’s unparalleled expertise and leadership, bolstering its position as a sought-after advisor to private and public healthcare stakeholders.

Ms. Autor boasts a distinguished career spanning over two decades within the FDA, culminating in her crucial role as Deputy Commissioner, overseeing all inspections and international operations. Before her tenure at the FDA, she served as a decorated federal prosecutor at the U.S. Department of Justice, further enriching her multi-faceted background.

Beyond her impressive government experience, Ms. Autor has also thrived in leadership positions within brand-name and generic pharmaceutical companies. Notably, she managed multiple regulatory functions for all AstraZeneca products globally, demonstrating her proficiency in navigating complex regulatory environments. Additionally, she led Global Quality at Mylan, ensuring the quality of an astounding 60 billion medication doses annually across numerous manufacturing sites and regulatory systems.

Michael Singer, Executive Chairman of HIC, expressed his delight regarding Ms. Autor’s appointment, stating, “We are honored to have Deb take the helm as our first CEO. Her unparalleled expertise and proven leadership within the life sciences industry are invaluable assets that will propel HIC to even greater heights.”

Ms. Autor’s extensive experience across regulatory affairs, quality, compliance, business strategy, policy, and law equips her with a unique and comprehensive understanding of the intricate dynamics within the healthcare landscape. This holistic perspective aligns perfectly with HIC’s core mission of providing comprehensive and strategic advisory services to life sciences organizations navigating the ever-evolving regulatory and commercial terrain.

As she assumes the reins at HIC, Ms. Autor’s primary focus will be capitalizing on the company’s deep bench of cross-functional experts, solidifying its position as a trusted advisor within the healthcare ecosystem. This strategic vision underscores HIC’s commitment to empowering its clients to navigate the complexities of the healthcare landscape and achieve their innovation goals.